Inventiva S.A.
IVA
株式のランク
#10619
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
株価
$3.24
時価総額
$764.93M
変化（1日）
-0.18%
変化（1年）
-19.27%
国
FR
取引 Inventiva S.A. (IVA)
カテゴリー
Healthcare
の時価総額 Inventiva S.A.(IVA)
時価総額: $764.93M
October 2026時点で、Inventiva S.A. の時価総額は $764.93M です。これは、当社のデータによると、Inventiva S.A. が世界で10619th番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
Inventiva S.A. の時価総額の履歴（2021 から 2026 まで）
